| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $772K | — | -53.7% |
| SG&A Expense | $1.7M | — | -22.7% |
| Operating Income | -$2.5M | — | +36.0% |
| Net Income | -$2.5M | — | +35.1% |
| EPS (Basic) | -$1.04 | — | +50.2% |
| EPS (Diluted) | -$1.04 | — | +50.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.3M | -42.4% | -68.5% |
| Current Assets | $2.9M | -33.9% | -64.1% |
| Total Assets | $2.9M | -33.9% | -64.0% |
| Current Liabilities | $1.1M | -32.9% | -42.1% |
| Total Liabilities | $1.1M | -32.9% | -42.1% |
| Stockholders' Equity | $1.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.0M | — | +35.4% |
| Capital Expenditures | $3K | — | +0.0% |
| Investing Cash Flow | -$3K | — | +0.0% |
| Financing Cash Flow | $1.3M | — | -33.9% |
| Free Cash Flow | -$3.0M | — | +35.4% |
| -70.6% |